In a recent study, patients receiving interventions designed to increase adherence to screenings for breast, cervical, or colorectal cancers were more likely to be up to date on any or all screenings.
In patients with at least 1 out of date recommended cancer screening for breast, cervical, or colorectal cancer, interventions designed to increase adherence to screening tests are more effective than standard treatment, according to a recent study published in JAMA Network Open.
Rural screening rates have fallen short of Healthy People 2030 goals for breast, cervical, and colorectal cancer, despite reduced mortality from screening adherence. Individuals in rural areas with under 10,000 residents have a crude cancer mortality rate 12 points higher than individuals in large metropolitan areas.
Sociodemographic factors influencing cancer screening rates include lower educational attainment, less screening knowledge, lower income, poor health care access, and greater social deprivation. Interventions could increase screening adherence and reduce the disparate cancer mortality seen among women living in rural areas.
To evaluate the effects of increased guidance on breast, cervical, and colorectal cancer screenings, investigators conducted a randomized clinical trial. Participants were recruited from 98 rural counties from October 20, 2016, to March 15, 2019.
Inclusion criteria included being aged 50 to 74 years, biological female sex, not up to date with 1 or more guideline-based cancer screening for women, able to speak English, not having a prior cancer diagnosis, and providing consent.US Preventive Task Force (USPSTF) data was used to determine if participants were up to date on cancer screenings.
In one intervention group, participants received an interactive DVD which allowed them to respond to prompts and receive feedback to encourage needed screenings. Information was provided based on the patient’s age, perceived cancer risk, family history of cancer, and barriers, benefits, and self-efficacy related to screening behavior.
A DVD/PN group saw women receiving a DVD similar to the DVD group, then a patient navigator telephone attempt within the following 4 weeks. Patient navigators included 2 Ohio residents who were social workers, trained by study investigators to be patient navigators.
Participants were randomly assigned to a DVD group, a DVD/PN group, or a usual group. Outcome data was collected through self-report and medical record review verification 12 months after DVD mailing. Screening tests at 12 months based on USPSTF guidelines were considered up to date.
At baseline and 12 months, participants reported sociodemographic and health care variables, cancers and recommended screening knowledge, smoking status, health beliefs, and plans to update screenings. Likert response options were used to evaluate knowledge and health beliefs for cancer screenings.
There were 963 participants in the final analysis, with a mean age of 58.6 years. A high school education level or less was reported by 16%, some college by 38%, and college or higher by 46%. Most participants were White, married, had an annual household income of $40,000 or more, and had health insurance.
Being up to date with all 3 cancer screenings at 12 months was seen in 10% of patients in the usual care group, 15% in the DVD group, and 30% in the DVD/PN group in an unadjusted model. The rates for being up to date with any 1 of 3 cancer screenings were 25%, 29%, and 49%, respectively.
These results showed a significant increase in women being up to date on screenings in the DVD/PN group. The DVD/PN group also saw a significant increase in efficacy where the DVD group did not in a covariate-adjusted model.
In another adjusted model, significant increases were observed in both the DVD and DVD/PN groups, with the DVD group having almost twice the odds of being up to date on all 3 screenings as the usual care group, and the DVD/PN groups having almost 6 times the odds of being up to date.
A significant association was found between screening status at baseline and status at 12 months. Being up to date with at least 1 cancer screening at baseline was associated with increased odds of being up to date on all screenings at 12 months.
Odds of being up to date at 12 months were also increased in patients aged under 65 years, planning to obtain a cancer screening within 6 months at baseline, with higher baseline self-efficacy scores, and with lower area deprivation index scores.
Overall, being up to date with breast, cervical, and colorectal cancer screenings was more often seen in intervention groups, indicating interventions designed to increase screening adherence are effective. Investigators concluded there is potential for implementing evidence-based interventions in remote midwestern US settings.
Reference
Champion VL, Paskett ED, Stump TE, et al. Comparative effectiveness of 2 interventions to increase breast, cervical, and colorectal cancer screening among women in the rural US: A randomized clinical trial. JAMA Netw Open. 2023;6(4):e2311004. doi:10.1001/jamanetworkopen.2023.11004
Study finds reduced CIN3+ risk from early HPV vaccination
April 16th 2024A recent study found that human papillomavirus vaccination when aged under 20 years, coupled with active surveillance for cervical intraepithelial neoplasia grade 2, significantly lowers the risk of cervical intraepithelial neoplasia grade 3 or cervical cancer.
Read More
Assessing Onclarity HPV assay safety and efficacy for cervical cancer screening
February 21st 2024A recent study evaluated the safety and effectiveness of the Onclarity HPV assay in detecting high-grade cervical disease, presenting findings on its comparability to predicate assays and potential for cost-saving benefits in screening practices.
Read More
Unifying radical hysterectomy classifications with the Querleu-Morrow
February 16th 2024Explore how the latest research underscores the efficacy of the 2017 Querleu-Morrow classification in defining radical hysterectomy extent, shedding light on surgical terminologies for cervical cancer management.
Read More
Protecting HIV-positive adolescents against high-risk HPV types
February 5th 2024A recent study found that the Gardasil quadrivalent HPV vaccine effectively shields HIV-positive adolescents from high-risk HPV types 16, 18, 6, and 11, shedding light on the potential for HPV vaccination to mitigate cancer risks in this vulnerable population.
Read More